Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed p…
| Periodo | 2026-12 | 2026-08 | 2026-08 | 2026-05 |
|---|---|---|---|---|
| Real | — | $-0.24 | — | $-1.09 |
| Estimado | $-1.45 | $-1.64 | $-1.64 | $-1.26 |
| Sorpresa | — | +85.4% | — | +13.5% |
| Métrica | DRUG | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.4% | — |
| Operating Margin | — | -34.4% | — |
| Net Margin | — | -32.5% | — |
| FCF Margin | — | -12.6% | — |
| ROE | -50.6% | -39.2% | -11.4% |
| ROA | -45.9% | -30.9% | -14.9% |
| Current Ratio | 11.32 | 2.73 | +8.59 |
| Debt / Equity | — | 0.28 | — |
| Tendencia (Piotroski) | FY24 | FY23 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -45.9% | — |
| ✗Flujo de caja operativo positivo | −CA$2M | −CA$7M |
| ✓Rentabilidad sobre activos al alza | -45.9% | -107.2% |
| ✓Caja operativa/activos supera al ROA | -30.3% | ROA -45.9% |
| –Menos deuda a largo plazo | — | — |
| ✗Mejor liquidez (ratio corriente) | 11.32 | 24.26 |
| ✗Sin aumentar el nº de acciones | 4M | 4M |
| –Margen bruto al alza | — | — |
| –Rotación de activos al alza | — | — |
BRIGHT MINDS BIOSCIENCES INC. cotiza a 51.30 USD y tiene una capitalización bursátil de $506M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud